Overview Dividends

(EHAB) Enhabit - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29332G1022

Home Health, Hospice, Therapy, Chronic Care, Palliative

EHAB EPS (Earnings per Share)

EPS Growth (3Y CAGR): -20.55%
EPS Trend (3Y Correlation): -0.4%

EHAB Revenue

Revenue Growth (3Y CAGR): -1.54%
Revenue Trend (3Y Correlation): -37.2%

Risk via 10d forecast
Volatility	55.8%
Value at Risk 5%th	75.4%

Reward
Sharpe Ratio	0.29
Alpha Jensen	-14.84

Character
Hurst Exponent	0.401
Beta	1.317

Drawdowns 3y
Max DD	59.30%
Mean DD	36.69%

Description: EHAB Enhabit October 24, 2025

Enhabit, Inc. (NYSE: EHAB) is a Dallas-based provider of home health and hospice services across the United States, offering a broad portfolio that includes skilled nursing, chronic disease management, therapy, and end-of-life care. The company rebranded from Encompass Health Home Health Holdings in March 2022 and has operated since 1998.

Key operational metrics (FY 2023) show revenue of roughly $1.1 billion, with a home-health segment contribution of about 68 % and a hospice contribution of 32 %. The firm reported an adjusted EBITDA margin near 7 %, reflecting the pressure of Medicare-centric reimbursement rates and the need for cost-efficient staffing models. Recent quarterly filings indicate a 4 % YoY increase in patient admissions, driven partly by the aging U.S. population and rising prevalence of chronic conditions such as diabetes and heart failure.

The home-health sector is currently expanding at a compound annual growth rate of 6-7 % (2022-2027), propelled by demographic trends, policy shifts favoring home-based care, and tighter hospital length-of-stay constraints. However, reimbursement uncertainty-particularly potential changes to Medicare’s Home Health Prospective Payment System-introduces upside/downside risk that Enhabit must navigate.

For a deeper quantitative assessment, you may find ValueRay’s analyst toolkit useful for benchmarking Enhabit against peers.

EHAB Stock Overview

Market Cap in USD	402m
Sub-Industry	Health Care Services
IPO / Inception	2022-07-01
Return 12m vs S&P 500	-5.98%
Analyst Rating	3.40 of 5

EHAB Dividends

Currently no dividends paid

EHAB Growth Ratios

CAGR	-13.52%
CAGR/Max DD Calmar Ratio	-0.23
CAGR/Mean DD Pain Ratio	-0.37
Current Volume	633.7k
Average Volume	407.4k

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (-11.9m TTM) > 0 and > 6% of Revenue (6% = 62.9m TTM)

FCFTA 0.05 (>2.0%) and ΔFCFTA 0.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 7.46% (prev 6.30%; Δ 1.17pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 62.2m > Net Income -11.9m (YES >=105%, WARN >=100%)

Net Debt (18.1m) to EBITDA (52.3m) ratio: 0.35 <= 3.0 (WARN <= 3.5)

Current Ratio 1.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (51.1m) change vs 12m ago 1.79% (target <= -2.0% for YES)

Gross Margin 61.40% (prev 46.56%; Δ 14.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 82.75% (prev 79.52%; Δ 3.22pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.74 (EBITDA TTM 52.3m / Interest Expense TTM 36.5m) >= 6 (WARN >= 3)

Altman Z'' 0.99

(A) 0.06 = (Total Current Assets 213.7m - Total Current Liabilities 135.5m) / Total Assets 1.23b

(B) 0.08 = Retained Earnings (Balance) 98.3m / Total Assets 1.23b

(D) 0.16 = Book Value of Equity 98.6m / Total Liabilities 631.0m

Total Rating: 0.99 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 48.66

1. Piotroski 5.50pt = 0.50

2. FCF Yield 13.75% = 5.0

3. FCF Margin 5.52% = 1.38

4. Debt/Equity 0.13 = 2.49

5. Debt/Ebitda 0.35 = 2.41

6. ROIC - WACC (= -7.95)% = -9.94

7. RoE -2.18% = -0.36

8. Rev. Trend -37.24% = -2.79

9. EPS Trend -0.42% = -0.02

What is the price of EHAB shares?

As of November 14, 2025, the stock is trading at USD 8.15 with a total of 633,729 shares traded.
Over the past week, the price has changed by +5.71%, over one month by +2.39%, over three months by +7.66% and over the past year by +7.10%.

Is Enhabit a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Enhabit (NYSE:EHAB) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 48.66 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EHAB is around 7.08 USD . This means that EHAB is currently overvalued and has a potential downside of -13.13%.

Is EHAB a buy, sell or hold?

Enhabit has received a consensus analysts rating of 3.40. Therefor, it is recommend to hold EHAB.

Strong Buy: 1
Buy: 0
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the EHAB price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	9.4	15.1%
Analysts Target Price	9.4	15.1%
ValueRay Target Price	8.1	-0.4%

EHAB Fundamental Data Overview November 10, 2025

Market Cap USD = 402.3m (402.3m USD * 1.0 USD.USD)
P/E Forward = 16.3399
P/S = 0.384
P/B = 0.7424
Beta = 1.317
Revenue TTM = 1.05b USD
EBIT TTM = 26.9m USD
EBITDA TTM = 52.3m USD
Long Term Debt = 492.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 35.2m USD (from shortTermDebt, last quarter)
Debt = 75.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 18.1m USD (from netDebt column, last quarter)
Enterprise Value = 420.4m USD (402.3m + Debt 75.0m - CCE 56.9m)
Interest Coverage Ratio = 0.74 (Ebit TTM 26.9m / Interest Expense TTM 36.5m)
FCF Yield = 13.75% (FCF TTM 57.8m / Enterprise Value 420.4m)
FCF Margin = 5.52% (FCF TTM 57.8m / Revenue TTM 1.05b)
Net Margin = -1.14% (Net Income TTM -11.9m / Revenue TTM 1.05b)
Gross Margin = 61.40% ((Revenue TTM 1.05b - Cost of Revenue TTM 404.5m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 46.94%)
Tobins Q-Ratio = 0.34 (Enterprise Value 420.4m / Total Assets 1.23b)
Interest Expense / Debt = 11.07% (Interest Expense 8.30m / Debt 75.0m)
Taxrate = -40.51% (negative due to tax credits) (-3.20m / 7.90m)
NOPAT = 37.8m (EBIT 26.9m * (1 - -40.51%)) [negative tax rate / tax credits]
Current Ratio = 1.58 (Total Current Assets 213.7m / Total Current Liabilities 135.5m)
Debt / Equity = 0.13 (Debt 75.0m / totalStockholderEquity, last quarter 566.8m)
Debt / EBITDA = 0.35 (Net Debt 18.1m / EBITDA 52.3m)
Debt / FCF = 0.31 (Net Debt 18.1m / FCF TTM 57.8m)
Total Stockholder Equity = 546.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.97% (Net Income -11.9m / Total Assets 1.23b)
RoE = -2.18% (Net Income TTM -11.9m / Total Stockholder Equity 546.5m)
RoCE = 2.59% (EBIT 26.9m / Capital Employed (Equity 546.5m + L.T.Debt 492.6m))
RoIC = 3.65% (NOPAT 37.8m / Invested Capital 1.03b)
WACC = 11.61% (E(402.3m)/V(477.3m) * Re(10.87%) + D(75.0m)/V(477.3m) * Rd(11.07%) * (1-Tc(-0.41)))
Discount Rate = 10.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 68.00% ; FCFE base≈55.9m ; Y1≈54.1m ; Y5≈53.7m
Fair Price DCF = 12.19 (DCF Value 617.1m / Shares Outstanding 50.6m; 5y FCF grow -4.44% → 3.0% )
EPS Correlation: -0.42 | EPS CAGR: -20.55% | SUE: 2.01 | # QB: 1
Revenue Correlation: -37.24 | Revenue CAGR: -1.54% | SUE: -0.84 | # QB: 0

Additional Sources for EHAB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle